Employers Hold the Line on GLP-1 Weight Loss Drug Coverage

Employer coverage of GLP-1 medications for both diabetes and obesity has flatlined, with a new survey showing no growth from last year and only a modest uptick from 2024 levels. Roughly 36% of employers currently cover GLP-1 drugs for both weight loss and diabetes management — unchanged from the prior year and only two percentage points above the 34% recorded in 2024, according to the survey.

The stagnation signals that many companies are actively resisting pressure to broaden access to the blockbuster class of drugs, which includes brand names like Ozempic and Wegovy. Rather than expanding coverage outright, a growing number of employers are reportedly seeking alternative strategies to manage costs and limit exposure to the high price tags associated with these medications.

Read more Novo Nordisk Sues Eli Lilly Over Allegedly Deceptive GLP-1 Ads →

The data underscores a widening tension between employee demand for GLP-1 therapies and corporate bottom lines. These drugs have surged in popularity as clinical evidence mounts around their effectiveness for weight management, yet their list prices remain a significant barrier for self-insured employers who bear the direct cost of claims.

For workers, the practical effect is that access to GLP-1 coverage continues to depend heavily on where they work — creating an uneven benefits landscape across industries and employer sizes. Analysts note that without broader mandates or significant price reductions, employer adoption is unlikely to accelerate meaningfully in the near term.

Continue reading at US Top News and Analysis.